In CRC, the thioredoxin-like enzyme Txl-2b (thioredoxin-like protein 2b) is overexpressed in most tumors and drives IκBα and p65 phosphorylation, nuclear p65 accumulation, and NF-κB–dependent expression of Cyclin D1, Bcl-2 family proteins, and Survivin; silencing Txl-2b reverses these effects, impeding proliferation and chemoresistance [152]. The gene discussed is BCL2; the disease is colorectal carcinoma.